19:28 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Leukemia; solid tumors Patient sample, cell culture and mouse studies suggest agonizing NR1D1 and NR1D2 may help solid tumors and leukemia. In tumor samples from glioblastoma patients, high NR1D2 expression correlated with survival. In...
23:30 , Jan 10, 2018 |  BC Extra  |  Preclinical News

Targeting cancer cell metabolism through circadian rhythm

A paper published in...
16:29 , Sep 28, 2017 |  BC Innovations  |  Translation in Brief

Bugs on the clock

Researchers from University of Texas Southwestern Medical Center have discovered a link between the gut microbiome and the circadian mechanisms that regulate body fat storage. Their findings implicate nuclear factor interleukin-3 regulated (NFIL3) as a...
07:00 , Apr 26, 2012 |  BC Innovations  |  Targets & Mechanisms

Pumping up the metabolic Rev-ERB

Two teams have shown that the nuclear receptors Rev-ERBAα and Rev-ERBAb play a central role in regulating the circadian clock and metabolism, 1,2 and a third group has found that agonizing both receptors treats obesity...
07:00 , Apr 19, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Nuclear receptor subfamily 1 group D member 1 (NR1D1; Rev-ERBAa); NR1D2 (Rev-ERBAb) Mouse studies suggest dual NR1D1 and NR1D2 agonists could help treat...
08:00 , Jan 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation; inflammatory disease Nuclear receptor subfamily 1 group D member 1 (NR1D1; REV-ERBAa) Cell culture and mouse studies suggest agonizing the circadian regulator NR1D1 could...